Daily Judi: Tuesday, August 23, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
The European Commission announced Monday that it has approved Gilead’s new antiretroviral medication, Lenacapavir. Gilead markets this treatment as Sunlenca. The California-based Gilead designed Sunlenca as a twice-yearly dose, intended to block HIV at multiple stages. Reported by MedCityNews, Gilead Chairman and CEO Daniel O’Day said, “Following today’s approval, it will now be the only twice-yearly treatment for people who struggle with multi-drug resistant HIV.”
Clinical Leader spoke with Benchmark Research's Chief Business Officer, Cynthia M. Dukes, PA, MT, about the COVID-19 pandemic and the United States government’s response (Operation Warp Speed). Dukes discusses how the pandemic accelerated the speed of clinical trials and subject enrollment.
Meanwhile, at the BMJ, a comprehensive look at 255 randomized trials. Its authors provide a systematic review of the clarity of research questions.
The CNS Summit 2022 will be held in Boca Raton, Florida, on November 17–20. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. More insight is provided in a recently posted experience video. Team Judi will be there!
Our Culture
“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.
Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”
–Stephen, Lead Engineer
About Judi
Judi helps clinical trial teams around the world come together to seamlessly manage complex workflows, interactions and insights, allowing them to do their best work. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
